Myelofibrosis Treatment Market Analysis & Forecast: 2025-2032

Global Myelofibrosis Treatment Market Overview

Myelofibrosis is a bone marrow disease that interrupts the blood cells production process in the body. Fibrous or scar tissue gets developed in the bone marrow leading to scarring causing insufficient blood cell production. Myelofibrosis is a rare type of chronic leukemia affecting blood production. The symptoms of myelofibrosis include severe anemia, fatigue, weakness, and enlarged spleen. The disease is usually found to occur in individuals over the age of 50 years. Myelofibrosis is of two types namely, primary myelofibrosis and secondary myelofibrosis. The treatment options are scarce but the U.S. Food and Drug Administration (FDA) approved Jakafi (Ruxolitinib), a drug developed by Novartis, which is the only approved product for the treatment of myelofibrosis that forms a major line of defense against the disease.

Myelofibrosis Treatment Market Size and Forecast – 2025 – 2032

The Myelofibrosis Treatment Market size is estimated to be valued at USD 1.2 billion in 2025 and is expected to reach USD 2.75 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.

Key Takeaways

• The JAK Inhibitors segment remains the primary contributor to the Myelofibrosis Treatment Market, capturing 45% market share, driven by ongoing approvals and expanded indications.

• Oral route of administration dominates treatment protocols, offering better patient compliance and convenience.

• Hospitals account for the largest market revenue among end users, owing to specialized hematology departments and advanced treatment facilities.

• North America holds a dominant industry share of approximately 40%, supported by strong healthcare infrastructure and active clinical research.

• Asia Pacific is the fastest-growing region, with projected CAGR exceeding 14%, driven by increasing healthcare investments and rising disease prevalence in India and China.

• Europe maintains a robust market position strengthened by favorable reimbursement policies and increasing patient access to innovative therapies.

Myelofibrosis Treatment Market – Segmentation Analysis

To learn more about this report, Download Free Sample

Myelofibrosis Treatment Market Insights, By Treatment Type

In terms of Treatment Type, the market is segmented into JAK Inhibitors, Immunomodulatory Agents, Chemotherapy, Stem Cell Transplantation, and Others among which JAK Inhibitors dominate the market share. Notably, JAK inhibitors have reshaped myelofibrosis treatment paradigms with their ability to target the underlying pathophysiology, holding approximately 45% of the treatment type market revenue. Their effectiveness in reducing splenomegaly and symptom burden drives sustained demand.

Myelofibrosis Treatment Market Insights, By Route of Administration

The Route of Administration segment comprises Oral, Injectable, and Others, with Oral administration dominating the market due to high patient adherence and convenience. Oral therapies such as ruxolitinib have become the standard of care, driving continuous growth and broad acceptance globally. Injectable routes are predominantly used for supportive care medications and emerging parenteral therapies with slower market penetration.

Myelofibrosis Treatment Market Insights, By End-User

Regarding End Users, the market is divided into Hospitals, Specialty Clinics, Homecare Settings, and Others, where Hospitals command the largest market share. Hospitals are equipped with hematology-oncology departments furnishing comprehensive treatment and diagnostic services crucial for managing myelofibrosis, sustaining high market revenue.

Myelofibrosis Treatment Market Insights, By Geography

To learn more about this report, Download Free Sample

North America Myelofibrosis Treatment Market Analysis and Trends

North America leads with approximately 40% market share, attributable to high healthcare expenditure, extensive R&D activities, and established pharmaceutical sectors. The U.S. government’s Orphan Drug Act continues to incentivize drug development, bolstering both innovation and commercialization efforts for myelofibrosis therapies.

Asia Pacific Myelofibrosis Treatment Market Analysis and Trends

Asia Pacific is the fastest-growing region, expected to register a CAGR exceeding 14%, driven by escalating disease prevalence, improved healthcare infrastructure, and proactive government initiatives in emerging markets such as China and India.

Myelofibrosis Treatment Market Outlook for Key Countries

United States Myelofibrosis Treatment Market Analysis and Trends

The USA significantly impacts the Myelofibrosis Treatment Market with a dominant share supported by robust clinical trial activity and reimbursement frameworks. The FDA’s fast-track approvals have expedited market entry of new drugs such as fedratinib, improving treatment choices and driving market revenue growth by nearly 15% annually. Leading pharmaceutical companies, including Incyte Corporation and Bristol-Myers Squibb, maintain strong R&D pipelines with ongoing late-stage trials targeting novel pathways, strengthening the country’s industry share.

India Myelofibrosis Treatment Market Analysis and Trends

India's growing myelofibrosis treatment market mirrors rising diagnosis rates and expanding healthcare access, contributing to the Asia Pacific region’s rapid growth. Government subsidy programs and increasing availability of generic formulations have improved treatment affordability. Indian firms are collaborating with multinational companies to conduct clinical studies and expand patient outreach, significantly influencing business growth and market dynamics in the region.

Analyst Opinion

• The surge in pipeline therapeutics and increasing approval rates of Janus kinase (JAK) inhibitors remain a critical driver in the myelofibrosis treatment market. In 2024, the approvals for next-generation JAK inhibitors expanded by 30%, significantly enhancing patient treatment outcomes and market revenue. This supply-side shift corroborates with a 20% increase in production capacity by pharmaceutical manufacturers specializing in oncology drugs.

• Patient demand for personalized medicine and improved diagnostic capabilities supports the growing market share of molecularly targeted therapies. Clinical trials involving combination therapies increased by over 25% in 2025 compared to 2023, highlighting a demand-side shift towards precision healthcare.

• The rising adoption of non-invasive diagnostic tools for bone marrow fibrosis evaluation has improved early detection rates, altering market dynamics significantly. Data from the U.S. hematology centers reveal a 15% reduction in diagnostic turnaround times in 2024, optimizing treatment initiation and healthcare spending.

• Market growth is also driven by emerging economies ramping up healthcare expenditure and facilitating access to innovative treatments. For instance, India and Brazil reported a 22% increase in myelofibrosis treatment reimbursements in 2024, boosting regional market share and contributing to the global market forecast.

Market Scope

Growth factors

The rise in myelofibrosis incidence worldwide due to better disease awareness and diagnosis is a major growth catalyst, with global epidemiological studies indicating a 6% year-over-year rise in new cases between 2023 and 2025. Advances in targeted therapies, especially the increasing accessibility of JAK inhibitors, contribute significantly to market growth, with sales volume growing by 28% in 2025 compared to 2023.

Another driver is the enhanced reimbursement infrastructure across developed and emerging markets, improving affordability and coverage for myelofibrosis treatments, as indicated by policy changes in the U.S. and parts of Europe increasing patient coverage by 18% in 2024. Hormone therapy is also utilized in certain cases to improve anemia in myelofibrosis patients, contributing to the range of available treatments.

Myelofibrosis Treatment Market Development

• In August 2025, An international phase 3 clinical trial of a new drug combination for treating the blood cancer myelofibrosis found that adding a second, experimental drug to standard treatment was more effective than the standard treatment alone. Further, adding the second drug did not significantly increase side effects. Memorial Sloan Kettering Cancer Center (MSK) enrolled the most patients in the trial.  

• In March 2025, GlaxoSmithKline Korea (GSK Korea) officially launched Omjjara (ingredient: momelotinib dihydrochloride hydrate), its new treatment for myelofibrosis. The business anticipates that Omjjara will improve splenomegaly and systemic symptoms, which are important therapeutic targets in the therapy of myelofibrosis, in addition to addressing the substantial unmet medical need for the management of anemia.

Market Trends

Emerging trends within the Myelofibrosis Treatment Market reveal a pivotal shift towards combination therapies involving JAK inhibitors and immune checkpoint modulators. Recent Phase III trial data from mid-2025 indicated a 35% improvement in progression-free survival with such regimens compared to monotherapy. Additionally, adoption of digital health platforms for real-time patient monitoring is gaining traction, with pilot programs in U.S. clinics reporting a 20% reduction in adverse event hospitalizations in 2024. Another notable trend is the increasing focus on developing allogeneic stem cell transplantation alternatives, particularly in Asia Pacific, driven by the high-cost barrier and transplant-associated complications in traditional therapies. This has spurred investments in CAR-T and gene editing platforms tailored for myelofibrosis, marking a significant market shift.

Key Players

• Incyte Corporation

• Novartis AG

• Bristol-Myers Squibb Company

• CTI BioPharma Corp.

• Sanofi S.A.

• Pfizer Inc.

• Aclaris Therapeutics

• Eli Lilly and Company

• AbbVie Inc.

• Geron Corporation

Competitive strategies within the market include Novartis capitalizing on its RUXOLITINIB portfolio expansion through partnerships for formulation improvements, achieving a 15% increase in patient adherence rates in 2024. Bristol-Myers Squibb employed an aggressive acquisition strategy to secure promising myelofibrosis candidates, which augmented its market presence by 10% in North America by the end of 2025. Additionally, Incyte Corporation focused on clinical collaborations to diversify its therapeutic pipeline, leading to a 25% increase in investigational new drug applications related to myelofibrosis.

Myelofibrosis Treatment Market Future Outlook

The future outlook for the Myelofibrosis Treatment Market is promising, with steady growth projected over the next decade. This growth is driven by advancements in targeted therapies such as JAK inhibitors, increased prevalence of myeloproliferative disorders, and heightened awareness leading to early diagnosis and treatment. Clinical laboratory tests play a critical role in the diagnosis and ongoing management of myelofibrosis, helping to identify patient needs and guide appropriate therapies. Regulatory support and expedited approvals for novel therapies are encouraging pharmaceutical investments and pipeline diversification. Hospitals play a crucial role in treatment delivery, offering multidisciplinary care and access to advanced therapies.

Additionally, ongoing clinical research focused on unmet needs in high-risk or refractory patients supports long-term market expansion. North America and Europe dominate the market due to high healthcare spending, favorable reimbursement policies, and rising patient populations. Emerging markets are also expected to contribute to growth owing to increasing healthcare infrastructure and awareness. Overall, the myelofibrosis treatment market is forecasted to experience moderate but consistent growth, expanding treatment options and improving patient outcomes worldwide.

Historical Analysis

• According to the American Society of Hematology 2016, myelofibrosis was a potentially life-threatening blood cancer that affected approximately 20,000 Americans. Asia Pacific was expected to hold a large share of the global market during the forecast period owing to increased disposable incomes, high geriatric population, and improved healthcare facilities.

• For instance, the development of a molecule, CYT387 or Momelotinib, by Gilead Sciences for treating primary myelofibrosis and the innovation of the current drug, ruxolitinib, by Incyte Corporation aimed to develop a substitute dosing strategy in patients with myelofibrosis.

Sources

• Primary Research interviews:

• Stem Cell Transplant Specialists

• Pharmacists (Oncology/ Hematology)

• Clinical Trial Investigators

• Databases:

• ClinicalTrials.gov

• WHO ICTRP (International Clinical Trials Registry Platform)

• FDA Adverse Event Reporting System (FAERS)

• Magazines:

• Hem/Onc Today

• Cancer Therapy Advisor

• Managed Care Magazine

• Journals:

• Haematologica

• British Journal of Haematology

• Cancer Medicine

• Newspapers:

• The Guardian (Healthcare & Science)

• The Wall Street Journal (Pharma & Healthcare)

• The Hindu (Health)

• Associations:

• Leukemia & Lymphoma Society (LLS)

• Myeloproliferative Neoplasm Research Foundation

• National Comprehensive Cancer Network (NCCN)